Loading...
Loading...
TIL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 2.0M |
| Gross Profit | -2.0M |
| Operating Expense | 33.9M |
| Operating I/L | -58.4M |
| Other Income/Expense | 1.4M |
| Interest Income | 2.1M |
| Pretax | -57.1M |
| Income Tax Expense | -0.7M |
| Net Income/Loss | -56.3M |
Instil Bio, Inc. is a clinical-stage biopharmaceutical company specializing in the development of cell therapy for cancer treatment. The company's primary focus is on the development of autologous tumor infiltrating lymphocyte (TIL) therapies, including ITIL-168 for indications such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer, as well as ITIL-306 targeting folate receptor alpha (FOLR1) with indications including gynecological, non-small cell lung cancer, renal cancer, and others.
